Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting

Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS - part III - analytical issues

(2013) Shabnam Tanqri et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Technical issues: flow cytometry and rare event analysis

(2013) B. D. Hedley et al.   International Journal of Laboratory Hematology

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

(2013) Andy C. Rawstron et al.   JOURNAL OF CLINICAL ONCOLOGY

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

(2013) N Puig et al.   LEUKEMIA

Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases

(2013) Prashant R. Tembhare et al.   LEUKEMIA RESEARCH

Critical assessment of automated flow cytometry data analysis techniques

(2013) Nima Aghaeepour et al.   NATURE METHODS

Overview of clinical flow cytometry data analysis: recent advances and future challenges

(2013) Carlos E. Pedreira et al.   TRENDS IN BIOTECHNOLOGY

Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma

(2012) Dingsheng Liu et al.   JOURNAL OF CLINICAL PATHOLOGY

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL

(2012) A C Rawstron et al.   LEUKEMIA

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

(2012) J J M van Dongen et al.   LEUKEMIA

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

(2011) B. Paiva et al.   BLOOD

Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma

(2011) Bruno Paiva et al.   JOURNAL OF CLINICAL ONCOLOGY

Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping

(2010) E S Costa et al.   LEUKEMIA

The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients

(2009) B. Paiva et al.   BLOOD

Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach

(2009) W. G. Nieto et al.   BLOOD

Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease

(2009) E. Domingo et al.   HAEMATOLOGICA

Instability of Immunophenotype in Plasma Cell Myeloma

(2008) Wenqing Cao et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

(2008) B. Paiva et al.   BLOOD

Generation of flow cytometry data files with a potentially infinite number of dimensions

(2008) Carlos E. Pedreira et al.   CYTOMETRY PART A

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

(2008) A. C. Rawstron et al.   HAEMATOLOGICA